REFERENCE
Veenstra DL, Spackman DE, Bisceglie A, Kowdley KV, Gish RG.Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: a cost-effectiveness analysis. Alimentary Pharmacology and Therapeutics 27: 1240-1252, No. 12, 15 Jun 2008
Rights and permissions
About this article
Cite this article
Entecavir outlasts the alernatives for affordable hep B therapy. Pharmacoecon. Outcomes News 559, 1 (2008). https://doi.org/10.2165/00151234-200805590-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00151234-200805590-00001